Stockwinners Market Radar for May 04, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:32 EDT Morphic director buys $47.25M in common stock - In a regulatory filing, Morphic disclosed that its director Timothy Springer bought 1.05M shares of common stock on May 3rd in a total transaction size of$42.25M.

18:41 EDT Kellogg CEO: We have high conviction that separating is the right thing to do - In an interview on CNBC's Mad Money, Steve Cahillane said both businesses will have solid balance sheets when the spinoff is complete. "We have strong routes to markets around the world," he noted The company has seen inflation like it hasn't in 30 years, but volumes have held up nicely, even with pricing. He expects deflation, but hasn't seen it yet. The cereal business has recovered nicely and he's excited about the prospects for that category.

18:30 EDT Cyxtera Technologies receives $50M in new financing - Cyxtera "announced that it has received $50 million in new financing from certain of its lenders, holding over two-thirds of its outstanding term loan, to support ongoing business operations. In connection with the new financing, Cyxtera has entered into a Restructuring Support Agreement with the Lenders to strengthen the Company's financial position and facilitate the business's long-term success."

18:03 EDT KeyCorp exec buys $733.5K in common stock - In a regulatory filing, KeyCorp disclosed that its Head of Institutional Bank Andrew Paine bought 75K shares of common stock on May 3rd in a total transaction size of $733.5K.

18:00 EDT Apple says India a 'major focus for us' - Says "couldn't be more excited" about enthusiasm for the brand in India. Says, "we view AI as huge and we'll continue to weave it into products on a thoughtful basis." Says "very pleased" with initial response to savings accounts. Sees "favorable" environment for component costs.

17:53 EDT Bristol-Myers EVP Vessey sells 50,385 common shares - In a regulatory filing, Bristol-Myers executive VP Rupert Vessey disclosed the sale of 50,385 common shares of the company on May 3 at a price of $67.06 per share.

17:48 EDT WillScot Mobile Mini increases share repurchase authorization to $1B - WillScot Mobile Mini announced that its board of directors has replenished the company's share repurchase authorization to $1B as of May 3.

17:36 EDT LMP Automotive declares $1.24 per share special cash dividend - LMP Automotive declared a special cash dividend of $1.24 per share. The dividend is anticipated to be paid on May 8 to all stockholders of record as of April 29.

17:31 EDT AMN Healthcare names Meredith Lapointe chief business officer - AMN Healthcare announced two executive leadership appointments as the total talent solutions company positions for continued growth and market leadership: Meredith Lapointe, has been named chief business officer. Patrick McCall has been named chief growth officer. These leaders will report directly to Cary Grace, president and CEO of AMN Healthcare, providing dedicated leadership over areas that empower the company's delivery of client-centric service and technology-enabled workforce solutions.

17:25 EDT Apple says 'particularly pleased' with performance in emerging markets - Says continued to face FX headwinds in Q2, which had an impact of more than 500 bps on results. Says continues to see strength in watch installed base. Says seeing strong growth in paid subscriptions. Continues to plan for annual dividend increases going forward. Comments taken from Q2 earnings conference call.

17:22 EDT Dropbox maintains long-term targets of 80%-82% in gross margins - Sees $1B in free cash flow by 2024 and 30%-32% in operating margin.

17:14 EDT Apellis spikes 8% after reporting quarterly results amid Syfovre launch

17:13 EDT Digital Media Solutions receives continued listing standard notice from NYSE - Digital Media Solutions announced that it received written notice on April 28, 2023, from the New York Stock Exchange, indicating that the Company is not in compliance with NYSE's continued listing standards which require it to maintain an average global market capitalization of at least $50.0 million over a consecutive 30-day trading period and, at the same time, a total stockholders' equity equal to or greater than $50.0 million. Under NYSE rules, the Company has a period of 45 days from receipt of the notice to submit a plan advising the NYSE of definitive actions the Company has taken, or is taking, that would bring it into compliance with the market capitalization listing standard within 18 months of receipt of the notice. The Company plans to notify the NYSE that it intends to submit a plan to cure the global market capitalization listing standard deficiency. The Company is currently evaluating its available options and developing a plan to regain compliance with the minimum global market capitalization requirement.

17:08 EDT Duckhorn Portfolio to acquire North Coast Winery and Vineyards for $55M - The Duckhorn Portfolio announced that it has entered into a definitive agreement to acquire a production winery and planted vineyards in Alexander Valley, Sonoma County, California. This acquisition will bolster the Company's production capacity and provide the Company with a fully operational and modern facility, with state-of-the-art winemaking equipment appropriate for premium wines. In addition to the production facility, the property also includes over seven acres of planted Cabernet Sauvignon. The transaction, which is subject to certain customary closing conditions, is expected to close in the fourth fiscal quarter of 2023. The purchase price of the transaction was approximately $55 million. The acquisition will be financed through the Company's existing credit facility.

16:53 EDT El Pollo Loco sees FY23 capital expenditures $25M-$29M - Sees FY23 tax rate 26.5%-27.5%.

16:46 EDT Blend Labs receives continued listing standard notice from NYSE - Blend Labs announced that it received notice on April 28, 2023 from the New York Stock Exchange that as of April 27, 2023 it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE's Listed Company Manual because the average closing price of the Company's Class A Common Stock was less than $1.00 per share over a consecutive 30 trading-day period. Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum price criteria. In accordance with Section 802.01C, the Company plans to notify the NYSE within 10 business days of its receipt of the Notice of its intent to cure the deficiency, which may include, if necessary, effecting a reverse stock split, subject to approval by the Board of Directors and stockholders of the Company. The Company is already undertaking business initiatives and other actions that it believes will increase stockholder value and drive share price increases.

16:46 EDT CACI, Torchlight AI announces strategic partnership over dark web exploration - CACI International Inc.'s Bluestone Analytics and Torchlight AI announced a strategic partnership to provide the DarkPursuit capability within the Torchlight Catalyst platform. This partnership will provide Torchlight customers, mainly Special Operations Forces (SOF), with safe and secure access to browse the open, deep, and dark web. "We are excited to partner with Torchlight to provide SOF customers with safe and secure access to Dark Web and open-source channels through the DarkPursuit infrastructure," said Meisha Lutsey, President of Operations Support and Services. "This partnership offers SOF customers a way to accelerate obtaining critical information that can give them an advantage over our adversaries." CACI's DarkPursuit is a capability within the DarkBlue Intelligence Suite that enables users to pivot from analysis and targeting activity to secure virtual browsing on the open, deep, and dark web.

16:44 EDT Banner Acquisition to redeem Class A common stock - Banner Acquisition Corp. announced that it will redeem all of its outstanding shares of Class A common stock sold as part of the units in the company's initial public offering, effective as of the close of business on or around May 16, because the company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation. The per-share redemption price for the public shares will be approximately $10.27. Funds in the company's trust account, including any interest thereon, will not be used to pay for any excise tax imposed under the Inflation Reduction Act of 2022. The company anticipates that the public shares will cease trading as of the open of business on May 15. As of the close of business on or around May 16, the public shares will be deemed cancelled and will represent only the right to receive the Redemption Amount.

16:42 EDT Adams Resources unit acquires 10.6 acres of land in Dayton, TX - Adams Resources & Energy announces that its subsidiary, Phoenix Oil, Inc. acquired approximately 10.6 acres of land in the Gulf Inland Industrial Park, located in Dayton, TX, to build a new processing facility with rail spur and siding, product storage, and truck rack. Phoenix will build new infrastructure to service its existing customers and to create opportunities for growing the business. This location is closer to the refining and petrochemical centers and provides Phoenix with ideal logistics to better serve their customers. In addition, Phoenix will relocate its headquarters from Humble, Texas to this new location.

16:41 EDT Expedia says broad travel demand remains strong - Says has only seen meaningful decrease is in car rental space. Says broad travel demand remains strong in post-pandemic environment. Says consumers have "shaken off" recession concerns and continue to travel. Says Hotels.com now back in "growth mode." Comments taken from Q1 earnings conference call.

16:38 EDT Scripps Sports, Vegas Golden Knights sign multi-year agreement - The Vegas Golden Knights and Scripps Sports have signed a multi-year agreement to bring all locally broadcast Golden Knights games for free to residents of Nevada and surrounding states within the team's broadcast territory. The agreement allows The E.W. Scripps Company (NASDAQ: SSP) to televise all non-nationally exclusive Golden Knights games with full distribution on cable, satellite and over-the-air television. Financial terms are not being disclosed. The deal has obtained the necessary approvals from the National Hockey League. Scripps will air Golden Knights games on its local station KMCC-TV, which is currently airing programming from ION, Scripps' national entertainment network. ION programming will continue to be available to Nevadans over-the-air, on pay TV and on connected TV platforms through a move to another Las Vegas broadcast channel. KMCC, channel 34, will be rebranded as an independent station before the 2023-24 NHL season begins. In addition to the Golden Knights games, the new KMCC will broadcast local and national news, local sports and additional entertainment programming. Scripps also owns the Las Vegas ABC affiliate, KTNV, which will provide a strong marketing platform for KMCC and the Golden Knights telecasts and has carried VGK preseason games since the franchise's inaugural season of 2017-18.

16:37 EDT Intuit names CEOs of LinkedIn, Zoom Video to board - Intuit (INTU) announced that it has appointed Ryan Roslansky, CEO of LinkedIn, and Eric S. Yuan, CEO and founder of Zoom Video Communications, to its board of directors.

16:36 EDT Apollo Global's Shutterfly names new CEO - Shutterfly announced that Sally Pofcher has joined the Company as Chief Executive Officer. Hilary Schneider, Shutterfly's former CEO, will transition to a strategic advisor to the Company's Board of Directors. Shutterfly is majority-owned by certain investment funds managed directly or indirectly by Apollo Global Management, Inc.

16:35 EDT Apple reports Q2 Services revenue $20.91B vs. $19.82B last year

16:34 EDT Coterra Energy sees FY23 oil production range at 87-93 MBopd - The company guides: "Estimate full-year 2023 Discretionary Cash Flow of approximately $3.6 billion, at recent strip prices. 2023 capital budget remains unchanged at $2.0-2.2 billion (accrued); see potential for 2H23 deflation. Estimate 2023 Free Cash Flow of approximately $1.6 billion at recent strip prices. 2023 oil production range increasing by 1.0 MBopd, to 87.0-93.0 MBopd "

16:34 EDT Jamf Holding appoints John Strosahl as CEO, succeeding Dean Hager - Jamf announced a CEO transition plan, appointing John Strosahl as Chief Executive Officer to succeed retiring Chief Executive Officer Dean Hager, effective September 2, 2023. "Mr. Strosahl, who currently serves as Jamf's President and Chief Operating Officer, has been with the company since 2015. Mr. Strosahl first joined the company to lead Jamf's global revenue organization as Chief Revenue Officer and was promoted to Jamf Chief Operating Officer in 2020 and President in 2022. Since joining Jamf, Mr. Strosahl has made an incredible impact on the business, including driving Jamf's shift from license revenue to recurring revenue and expanding Jamf's reach globally. Mr. Hager will remain a member of Jamf's Board of Directors following his retirement as Chief Executive Officer and will work closely with Mr. Strosahl to facilitate a seamless transition. Mr. Strosahl will also join Jamf's Board of Directors, effective concurrently with his promotion to Chief Executive Officer."

16:34 EDT Apple reports Q2 Mac sales $7.17B vs. $10.44B last year

16:33 EDT Apple boosts quarterly dividend by 4% to 24c per share - Apple's board of directors has declared a cash dividend of 24c per share of the company's common stock, an increase of 4%. The dividend is payable on May 18, to shareholders of record as of the close of business on May 15. The board of directors has also authorized an additional program to repurchase up to $90B of the company's common stock.

16:32 EDT Apple announces $90B increase to share repurchase plan - The company said, "Our year-over-year business performance improved compared to the December quarter, and we generated strong operating cash flow of $28.6 billion while returning over $23 billion to shareholders during the quarter. Given our confidence in Apple's future and the value we see in our stock, our Board has authorized an additional $90 billion for share repurchases. We are also raising our quarterly dividend for the eleventh year in a row."

16:31 EDT Apple CEO says iPhone hit Q2 record despite 'challenging' environment - Apple CEO Tim Cook said in today's earnings release, "We are pleased to report an all-time record in Services and a March quarter record for iPhone despite the challenging macroeconomic environment, and to have our installed base of active devices reach an all-time high. We continue to invest for the long term and lead with our values, including making major progress toward building carbon neutral products and supply chains by 2030."

16:24 EDT Northern Oil reaffirms 2023 guidance for production, capital expenditures - The company sees annual production 91,000 - 96,000 Boe per day.

16:18 EDT Momentive sees STG transaction closing in Q2 or Q3 - On March 13, 2023, Momentive announced it had entered into a definitive agreement to be acquired by an investor consortium led by Symphony Technology Group in an all cash transaction that values Momentive at approximately $1.5 billion. On April 27, 2023, the Company filed its definitive proxy statement related to the proposed acquisition and announced it will hold a special meeting of stockholders via live webcast on May 31, 2023 at 9:00 a.m. PT to approve the transaction. The transaction is expected to close in the second or third quarter of 2023, subject to customary closing conditions, including approval by Momentive shareholders and the receipt of required regulatory approvals. The transaction is not subject to a financing condition. In light of the Company's pending acquisition, Momentive will not host a conference call or live webcast to discuss these financial results. Additionally, the Company is not providing financial guidance for Q2 2023 and full year 2023.

16:17 EDT Texas Roadhouse sees FY23 comparable restaurant sales growth - Sees FY23 capital expenditures $265M. The company said, "Comparable restaurant sales at company restaurants for the first five weeks of our second quarter of fiscal 2023 increased 8.6% compared to 2022. In addition, the Company implemented a menu price increase of approximately 2.2% in late March."

16:16 EDT Block reports 30M monthly Cash App Card actives in March, up 34% y/y

16:14 EDT Graham Holdings to repurchase up to 500,000 class B common shares - Graham Holdings Company announced that its Board of Directors has authorized the Company to acquire up to 500,000 shares of its Class B common stock. The Company did not announce a ceiling price or time limit for the purchases. As of April 28, 2023, there were 3,778,767 Class B shares outstanding.

16:08 EDT nLight awarded $86M contract to develop high energy laser - nLIGHT announced that it has been awarded an $86 million contract to produce a High Energy Laser (HEL) prototype for the next phase of development in support of the U.S. Department of Defense's (DoD) High Energy Laser Scaling Initiative (HELSI). The Office of the Under Secretary of Defense for Research & Engineering selected nLIGHT in 2019 to utilize its coherent beam combined (CBC) architecture to produce a 300 kW class high energy laser as part of the first phase of the HELSI program. In 2022, nLIGHT demonstrated power exceeding HELSI program objectives and the scalability of our CBC architecture. Today's award is part of a multi-year development program that is expected to commence in the third calendar quarter of 2023.

16:03 EDT Schrodinger backs FY23 financial guidance - As of May 4, 2023, Schrodinger maintained its financial guidance for the fiscal year ending December 31, 2023: Software revenue growth is expected to be in the range of 13 to 17 percent. Drug discovery revenue is expected to range from $70 million to $90 million. Software gross margin is expected to be similar to software gross margin for the full year 2022. Operating expense growth in 2023 is expected to be significantly lower than operating expense growth in 2022 and to be similar to revenue growth in 2023. Cash used for operating activities in 2023 is expected to be below cash used for operating activities in 2022. For the second quarter of 2023, software revenue is expected to range from $27 million to $31 million.

15:46 EDT Apple launches 20 new games for its Apple Arcade service - Apple announced 20 new titles launching on Apple Arcade, Apple's game subscription service that offers unlimited access to over 200 incredibly fun games. The new titles include WHAT THE CAR?, TMNT Splintered Fate, Disney SpellStruck, and Cityscapes: Sim Builder, all of which are only available on Apple Arcade. The expansion also adds popular games from the App Store to the service, including Temple Run+, Playdead's LIMBO+, PPKP+, and more."Apple Arcade brings together hundreds of fun titles in one gaming destination for our users to discover and enjoy," said Alex Rofman, Apple's senior director of Apple Arcade. "Today's launch boosts our award-winning catalog with 20 new games people will love playing and sharing with their friends and families." Reference Link

15:15 EDT Datadog jumps 15% after reporting quarterly results and guidance - Shares of Datadog, a monitoring and security platform for cloud applications, are up $9.37 per share or over 14% to $75.21 after reporting quarterly results that exceeded analyst estimates earlier on Thursday. For the first quarter the company posted EPS of 28c on revenue of $482M, ahead of analyst estimates. The company also reported its current view for 2023 results, with its EPS view ahead of analyst expectations. We are pleased with our execution in the first quarter, with 33% year-over-year revenue growth, continued customer growth, and increased multi-product adoption by our customers," said Olivier Pomel, co-founder and CEO of Datadog. Pomel added, "We continue to deliver innovation to our customers, including the recent launch of our Data Streams Monitoring and Application Vulnerability Management products. With our broadening observability and security platform, our customers can monitor, manage, secure, and drive value from their complex and ephemeral cloud environments." Reference Link

14:53 EDT SoFi Technologies CEO Noto buys 50K shares of company stock - SoFi Technologies CEO Anthony Noto disclosed in a regulatory filing that he had purchased 50,000 shares of company stock at $4.73 per share on May 4, for a total transaction amount of $236,705.

13:54 EDT TFS Financial director Weir purchases $137K in company shares - Director of TFS Financial Daniel Weir disclosed in a regulatory filing that he had purchased 11,500 shares of company stock at $11.91 per share on May 23, for a total transaction amount $136,981.

13:17 EDT Moderna up 5% after Q1 results beat estimates - Shares of Moderna are up $6.77, or 5%, to $136.91 in early afternoon trading after the company earlier reported Q1 revenue of $1.9B, topping the analyst consensus of $1.06B, and GAAP diluted EPS of 19c, beating the the analyst consensus forecast for a loss of ($1.59) per share. COVID-19 vaccine sales to Europe were $0.6B and sales to the rest of the world were $1.3B in the first quarter. "We had a strong first quarter, with $1.9B in revenue, clearly indicating that we are on our way to deliver on the $5B of signed Advance Purchase Agreements for 2023. In addition, we are encouraged by the progress of new COVID-19 vaccine contracts in the U.S. for this fall with pharmacy chains, hospital networks and multiple U.S. government agencies. Similar discussions are ongoing with Japan, the EU, and other key markets such as Australia, which recently ordered additional COVID-19 vaccines," said Stephane Bancel, CEO of Moderna. "The total of $1.8B in sales represents the vast majority of the projected $2B in sales from 2022 deferrals expected in the first half of 2023. The company reiterates its expectation of 2023 minimum sales of approximately $5.0B from previously announced COVID-19 vaccine Advanced Purchase Agreements. The company estimates the U.S. annual COVID-19 market to be 100 million doses," Moderna stated. Reference Link

13:08 EDT DZS to be platinum sponsor for BREKO Jahrestagung 2023 - DZS announced that the company will be a Platinum Sponsor of the German Broadband Association's Annual General Meeting, being held in Berlin on November 30, 2023.

13:03 EDT Sigmatron enters agreement with secured lenders, sells position in Wagz - SigmaTron International reached an agreement with its secured lenders going forward and sold a majority position of its wholly owned subsidiary, Wagz. As previously reported on March 20, 2023, via Form 8-K, during the preparation of the Company's third quarter financial statements, it was determined that updated projections resulted in a triggering event for the Company's goodwill and long-lived asset groups. Under GAAP, the review resulted in the Company concluding that the carrying amounts for the goodwill and long-lived asset groups were impaired, and the Company would incur non-cash impairment charges of approximately $23.1M. These impairment charges coupled with Wagz' operating losses resulted in the Company's failure to maintain certain financial covenants and ratios imposed by, and as a result triggered events of default under, the Company's credit agreements with J.P. Morgan Chase Bank, N.A. and TCW Asset Management Company, as Administrative Agent. Subsequent to that report on Form 8-K, on March 27, 2023, the Company reported receiving a delinquency notification letter from Nasdaq indicating that the Company was not in compliance with the continued listing requirements of Nasdaq for failing to timely file the Company's Form 10-Q for the fiscal quarter ended January 31, 2023. This notification also constituted a default under our credit agreements with our Secured Lenders. During fiscal year 2023 Wagz was in the process of developing three new products that were scheduled to be released during the middle of calendar year 2023. Sales of existing products during this development period did not materialize to expectations and resulted in a significantly higher level of losses and cash consumption than anticipated. Sales were negatively impacted by a shortage of parts for production for several months, resulting in missing the holiday season for sales, a slowing economy relating to inflation and a slower than anticipated acceptance of the product by the market. Thus, when projections were updated, it was determined that there was an impairment, as discussed above. Since determining the default, the Company negotiated with its Secured Lenders to reach an agreement to settle the events of default. As a result of negotiations with the Secured Lenders, while the core EMS business remained strong, it was decided that the Company would need to exit the Pet Tech business that was conducted through Wagz. The solution that was reached was the sale of 81% of Wagz to Vynetic, LLC, which would become the majority shareholder of Wagz. The Company would retain a 19% ownership position in Wagz as a passive investor at closing. The Company would provide a $900,000 working capital loan to Wagz during the month of April and during which time Vynetic, LLC would raise capital to support Wagz going forward. That transaction closed on April 28, 2023, and is effective as of April 1, 2023. Under the transaction, the Company has no further financial obligations or requirements to Wagz going forward beyond the initial working capital loan. The Company agreed to work with Wagz as an EMS provider pursuant to a manufacturing agreement but did not commit to extending any further financial support. The Company expects that the transaction will allow it to potentially recover some of the assets that it will write off as of April 30, 2023. In conjunction with the transaction, the Secured Lenders have agreed to waive all covenant violations and events of default under our credit agreements through March 31, 2023. In addition, the agreements have been amended going forward under terms that the Company believes will support its EMS business. With all such covenant violations and events of default being waived and with amended agreements in place, the Company believes it is now in a position to complete its third quarter financial statements and file its Form 10-Q prior to the Nasdaq compliance deadline of May 22, 2023. Once that report is filed, the Company will work on its fourth quarter and fiscal year financial statements and currently expects that those will be timely filed.

12:42 EDT MoneyGram trading resumes

12:37 EDT MoneyGram trading halted, volatility trading pause

12:22 EDT Microsoft's Spencer says Xbox will showcase brand new games at June showcase - During an interview with the Kinda Funny Xcast, a podcast covering Microsoft's gaming ambitions, Xbox Gaming CEO Phil Spencer said that the company will announce brand new games at its June showcase. Spencer added that Xbox Game Studios has games coming out every quarter in the future that will "surprise and delight" players, though he noted that "not every game we ship is for everybody."

12:11 EDT Atlas Lithium Corp trading halted, volatility trading pause

12:00 EDT Western Alliance falls -38.8% - Western Alliance is down -38.8%, or -$11.48 to $18.09.

12:00 EDT Lemonade rises 25.6% - Lemonade is up 25.6%, or $2.84 to $13.93.

12:00 EDT Arconic rises 27.5% - Arconic is up 27.5%, or $6.20 to $28.75.

11:55 EDT Microsoft's Spencer 'disappointed' with reception to Xbox exclusive 'Redfall' - During an interview with the Kinda Funny Xcast, a podcast covering Microsoft's gaming ambitions, Xbox Gaming CEO Phil Spencer said that the critical response to "Redfall," an Xbox console exclusive that released this week to poor reviews, was "not what we wanted" and that nothing is more difficult than "disappointing the Xbox community." "I'm disappointed," Spencer said. "I'm upset with myself." The executive noted that while there were clearly quality issues with the game's release, Xbox as a business will never push against the "creative aspirations" of its internal development teams, and that having games release to low 60s scores on Metacritic is just part of video game publishing.

11:31 EDT NCR Corp. names Joseph Reece chairman of the board - NCR Corporation announced Joseph "Joe" Reece, co-founder and managing partner of SilverBox Capital LLC, was elected chairman of its Board of Directors, effective May 2. Reece became an NCR director and was appointed independent lead director on November 4, 2022. He has more than 35 years of experience advising public and private corporations and boards. "I am humbled by the board's confidence in my leadership," said Reece. "I look forward to continued partnership with the NCR management team as we work to complete our transition into two publicly traded companies, enhancing shareholder value and keeping our customers first." Frank R. Martire, who was named executive chairman in April 2018, has retired

11:25 EDT Western Alliance says not exploring sale, hasn't hired advisor on options

11:12 EDT Kiromic BioPharma trading resumes

11:05 EDT Playstudios enters licensing deal with IGT - PLAYSTUDIOS (MYPS) announced its licensing deal with global gaming leader IGT, a wholly-owned subsidiary of International Game Technology PLC (IGT). For the first time, PLAYSTUDIOS can use popular IGT content within its chance-based casual games. The first three content titles scheduled for release are: "Wolf Run Eclipse," "Money Mania Pharaoh's Fortune" and "Wheel of Fortune Cash Link Australian Outback." The new games based on the above content will be available in PLAYSTUDIOS' myVEGAS Slots later this year.

10:54 EDT TOP Financial Group Ltd trading resumes

10:52 EDT Zions Bancorp trading resumes

10:47 EDT Western Alliance refutes FT report with shares down 62% to $11.35

10:47 EDT Metropolitan Bank Holding Corp trading halted, volatility trading pause

10:31 EDT Western Alliance extends selloff, shares down 53% to $13.78

10:23 EDT Western Alliance sinks 45% to $16.19 after trading resumes from halt

10:20 EDT Western Alliance drops over 30% to $20.59 after report says exploring options

10:16 EDT Atlas Lithium sinks 15% to $25.43 after Bleecker Street short report

10:09 EDT Enviva trading halted, volatility trading pause

10:05 EDT Cinedigm, ViX reach agreement for The Bob Ross Channel en Espanol - Cinedigm announced that its popular streaming channel The Bob Ross Channel en Espanol has launched today on ViX as a free ad-supported streaming television channel in the U.S. and Latin America excluding Brazil. Owned by TelevisaUnivision, ViX is the leading Spanish-language streaming service in the world.

10:02 EDT Precipio enters agreement with new customer for HemeScreen - Precipio announces another agreement with a new customer to bring HemeScreen technology into their laboratory. With each additional customer, Precipio continues to execute on its strategy, converting pipeline prospects to actual customers, and progressing towards breakeven.

10:00 EDT First Horizon falls -40.1% - First Horizon is down -40.1%, or -$6.04 to $9.01.

10:00 EDT Shopify rises 22.3% - Shopify is up 22.3%, or $10.34 to $56.61.

10:00 EDT Arconic rises 27.5% - Arconic is up 27.5%, or $6.21 to $28.75.

09:51 EDT Veracyte to present findings on TERT promoter gene mutations at AACE 2023 - Veracyte announced findings from a large-scale, systematic literature review showing that TERT promoter gene mutations in thyroid nodules deemed indeterminate by cytopathology are rare, but have a high risk of malignancy and, in certain cases, are associated with aggressive tumor behavior. The data are being presented at the American Association of Clinical Endocrinology 2023 Annual Meeting, being held May 4-6 in Seattle, and reinforce the value of Veracyte's expanded Afirma offering, which now includes TERT promoter mutation testing. For the study, Veracyte and external researchers systematically searched and reviewed 26 manuscripts published between 2014 and 2022 and identified a total of 77 TERT promoter-mutated indeterminate thyroid nodules with histologic correlates. They then calculated the risk of malignancy for all nodules, as well as the risk for those with isolated TERT promoter mutations, and with co-mutations in the RAS family of genes and with BRAFV600E. When relevant information was available, the researchers also determined the proportion of aggressive cancers in each group based on the tumors' histopathology findings. Overall, 84% of TERT promoter-mutated indeterminate nodules were malignant. There was no difference in the malignancy rate of nodules with isolated TERT promoter mutations compared to those with TERT promoter + RAS family co-mutations, nor was there a difference in the proportion of cancers with aggressive histology between these two groups. Of the five TERT promoter + BRAFV600E co-mutated nodules, all were malignant and 60% were described as aggressive. The new study findings underscore the value of Veracyte's recent expansion of its Afirma offering to include TERT promoter mutation testing, with a goal of helping physicians further personalize diagnosis and treatment for their patients with thyroid nodules.

09:49 EDT First Horizon trading halted, volatility trading pause

09:47 EDT Sabre targeting $900M of AEBITDA in 2025

09:47 EDT First Horizon falls -36.8% - First Horizon is down -36.8%, or -$5.54 to $9.51.

09:47 EDT Lemonade rises 17.2% - Lemonade is up 17.2%, or $1.91 to $13.00.

09:47 EDT Arconic rises 26.6% - Arconic is up 26.6%, or $6.00 to $28.55.

09:46 EDT Western Alliance trading halted, volatility trading pause

09:45 EDT Aviat Networks trading resumes

09:41 EDT Harbor Custom Development Inc trading resumes

09:40 EDT HUB Security raises up to $16M in growth investment from Lind Partners - HUB Cyber Security has entered into an agreement for up to $16M in gross proceeds from Lind Global Asset Management VI LLC, an investment entity managed by The Lind Partners, a New York based institutional fund manager. This investment is expected to provide HUB Security with additional resources to fuel its rapid growth and development, enhance its financial stability, and enable the Company to pursue its future plans. Under the terms of the agreement with Lind, HUB Security will have access to up to $16M in convertible debt financing in three tranches, which will mature over a two year period. Upon the closing of this transaction, the Company will have immediate access to the first tranche of $4.5M, and will have access to the remaining two tranches totaling $11.5M, upon the fulfillment of certain conditions.

09:38 EDT Mangoceuticals appoints Amanda Hammer as new COO - Mangoceuticals announced the appointment of Amanda Hammer as Chief Operating Officer. "As COO, Hammer will be responsible for helping MangoRx work to scale its operations and expand its presence in the US market. Hammer will manage the day-to-day operations of MangoRx as well as oversee its eCommerce channels, marketing, web services, human resources, compliance, and communications departments," the company stated. "We couldn't be more excited to place our future in the very capable hands of a top tier person like Amanda. The objective now is scaling up and delivering rapid growth to our stakeholders. Amanda has delivered on that objective in the past and we believe that she understands what needs to be done at MangoRx to repeat that success.," added Jacob Cohen, the company's co-founder and CEO.

09:37 EDT Envista Holdings trading halted, volatility trading pause

09:35 EDT Aviat Networks trading halted, volatility trading pause

09:32 EDT TripAdvisor trading halted, volatility trading pause

09:31 EDT Harbor Custom Development Inc trading halted, volatility trading pause

09:30 EDT PacWest Bancorp trading halted, volatility trading pause

09:29 EDT Revolve Group says April sales are down 7% from last year - In the company's Q1 earnings announcement yesterday, Revolve Group stated: "Net sales in April 2023 decreased approximately 7% year-over-year against a difficult prior-year comparison and amidst an increasingly uncertain macroeconomic environment highlighted by consumer inflationary pressures, U.S. Department of Commerce reports of decelerating consumer spending on apparel in recent months and continued foreign exchange headwinds year-over-year."

09:28 EDT AMG Advanced Metallurgical announces results of annual general meeting - AMG Advanced Metallurgical Group announced that during its Annual General Meeting held on May 4, 2023, shareholders approved all agenda items presented, including the reappointment of Dr. Heinz Schimmelbusch as Chief Executive Officer and Chairman of the Management Board for an additional term of two years, with effect from May 4, 2023. During the meeting, Professor Steve Hanke and Mr. Herb Depp were reappointed as independent members of the Supervisory Board for terms of two years each, beginning May 4, 2023. Ms. Dagmar Bottenbruch has decided to step down from AMG's Supervisory Board in view of other pressing priorities in her career, having served on AMG's Supervisory Board since 2019. Given the vacancy created by the departure of Ms. Bottenbruch, Dr. Anne Roby was appointed as an independent member of the Supervisory Board for a term of four years beginning May 4, 2023 . Approval was also granted for the Company's articles of association to be amended to accommodate the name change of the Company to ''AMG Critical Materials N.V.'' The reason for the change from AMG Advanced Metallurgical Group N.V. is explained in the Letter to Shareholders of the 2022 Annual Report.

09:26 EDT Enviva announces $100M repurchase program - Enviva announced last night that it can repurchase up to $100M in shares of the company's common stock under share repurchase program authorized by the board of directors. This is the company's first authorization for share repurchases since its founding. The company said, "We recognize this is an important departure from the plan we laid out at our Investor Day a month ago, but a lot has changed since then. Compared to our expectations, while our cost position has trended in the right direction, it has done so at a much slower pace than we had anticipated, in part due to slower volume growth, and in part due to a higher spend profile for the volume growth we did achieve. We know what the specific issues are: contract labor is too high, discipline around repairs and maintenance spend is insufficient, wood input costs need to come down further and stay there, and utilization rates at specific plants need to improve and stabilize at those improved levels. Because of where we are in our journey to bend our cost curve down while bending our production curve up, we feel it is prudent to take a much more conservative view of what our business can realistically achieve over the next eight months. Against this backdrop of operational challenges, we are undergoing an extensive review of where we are allocating our capital. We believe we have more accretive capital allocation alternatives, which start with improving returns from our existing fleet of assets, growing our fully contracted asset base, managing liquidity and leverage, and also include the potential to opportunistically repurchase our shares in the open market, which we believe have traded below their intrinsic value for some time."

09:23 EDT Tejon Ranch to aggressively pursue commercial/industrial development - The company said, "The Company will continue to aggressively pursue commercial/industrial development, multi-family development, leasing, sales, and investment within TRCC and its joint ventures. The Company will also continue to invest in its residential projects, including Mountain Village at Tejon Ranch, Centennial at Tejon Ranch and Grapevine at Tejon Ranch. California is one of the most highly regulated states in which to engage in real estate development and, assuch, natural delays, including those resulting from litigation, can be reasonably anticipated. Accordingly, throughout the next few years, the Company expects net income to fluctuate from year-to-year based on commodity prices, production within its farming and mineral resources segments, and the timing of land sales and leasing of land within its industrial developments. Water sales opportunities each year are impacted by the total precipitation and snowpack runoff in Northern California from winter storms, as well as California State Water Project, or SWP, allocations. The current SWP allocation is at 100% of contract amounts, so the Company anticipates that the demand for its water will be lower than in previous years when the SWP allocation was significantly lower. The Company's farming segment will continue to be impacted by higher production costs related to fuel, fertilizer, pest control, and labor. Almond prices showed slight improvement in the 2023 first quarter, however, higher than historically normal inventory levels is anticipated to have an adverse effect on prices for the remainder of this year. The Company remains focused on managing cash expenditures, including but not limited to, reducing capital expenditures, consulting services and re-focusing hiring efforts. In addition, we continue to evaluate opportunities to strengthen our financial position by entering into new financing arrangements, as appropriate."

09:22 EDT Lilium Jet enters powered test campaign at DNW facility - Lilium announced the start of wind tunnel testing on a complete 1 to 2.5 scale Lilium Jet model, including working engines and flap actuators, at the German-Dutch Wind Tunnels, DNW, facility in Marknesse, Netherlands. This latest campaign follows Lilium's previous successful wind tunnel testing of aircraft sections in 2021 and 2022 and represents a major milestone in the development of the type-conforming aircraft. Having started in early May, the testing will enable Lilium to obtain a comprehensive aerodynamic dataset to validate its flight physics and performance predictions. The dataset will cover the complete aircraft flight envelope from hover to cruise. Alastair McIntosh, Chief Technology Officer, Lilium said "This is an important step in our aircraft program and it is very exciting to see this large-scale Lilium Jet model with working engines and wing flaps. We've been enormously impressed by the cooperation with DNW so far and the support provided by TGR-E and IBK. We look forward to generating vast amounts of aerodynamics data on the aircraft and building further confidence in our design tools as we prepare for the start of final assembly later this year."

09:20 EDT Legend Power, Sparta Group enter agreement for SmartGATE - Sparta Group has inked a deal with Legend Power Systems, that will give Sparta Group the ability to add SmartGATE, a sophisticated active power management system to its suite of power quality optimization technologies. Sparta's Energy division has been largely focused on helping industrial clients reduce energy waste, and now this agreement with Legend Power means Sparta can expand its energy optimization efforts to a wider market of commercial clients.

09:17 EDT GT Biopharma names Casamento to board of directors - GT Biopharma (GTBP) has named Charles Casamento to fill a vacant seat on the Board and to serve as a member of the Audit Committee of the Board, the Compensation Committee of the Board and the Nominating and Corporate Governance Committee of the Board as of May 1, 2023. Concurrently, Alan Urban resigned as a member of the Board of Directors in order to pursue new career endeavors. Casamento is currently executive director and principal of The Sage Group (SGPYY), a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007.

09:16 EDT Zoom Video receives Unified License with Access from DoT, Government of India - Zoom announced that it has received the Unified License with Access - All/PAN India, NLD National Long Distance, and ILD - International Long Distance from the Department of Telecommunications, FoT, Government of India. With these licenses, the company will be able to offer Zoom Phone, its industry leading cloud PBX service, to multinational corporations and businesses operating in India. "We are thrilled and proud to receive the unified licenses from the Department of Telecommunications. With Zoom Phone, India businesses and multinational corporations can support hybrid work environments, foster greater collaboration among employees and elevate the customer experience," said Abe Smith, Head of International, Zoom. "This important milestone underscores our continued focus in countries like India, a strategic growth market for Zoom, and our commitment to bringing new and innovative collaboration solutions to our customers."

09:15 EDT AB InBev says beer industry in U.S. 'remains resilient' - Says has "significantly increased" investment in Bud Light brand in U.S. Expects to triple media spend on Bud Light over the summer. Says Bud Light drop represents about 1% of global volume. Says middle Americas continue to produce strong results. Comments taken from Q1 earnings conference call.

09:13 EDT Outbrain announces senior leadership appointments - Outbrain announced key promotions to scale global operations, drive innovation, and expand Outbrain's offerings for brands, advertisers, and publishers. These appointments follow Alexander Erlmeier's promotion to Chief Revenue Officer in October 2022. The leadership appointments include: Ayal Steiner - Executive Vice President, Brand Solutions - overseeing development of innovative solutions for brands and agencies looking to drive measurable outcomes and deeper engagement with audiences. Stephanie Himoff - Executive Vice President, Global Publishers - leading our strategic publisher initiatives on a global scale. Sarah Baird - Senior Vice President, Revenue Operations - leading revenue operations and enablement functions to provide strategies designed to support clients at scale. Craig Hughes - Senior Vice President, Corporate Development and Strategy; General Manager, Video - driving Outbrain's video strategy and business globally, and managing strategic initiatives and partnerships to deepen Outbrain's industry presence. Klaus Ludemann - Senior Vice President, Programmatic and Partnerships - managing programmatic partnerships and adoption in service of advertisers and publishers. Guy Yagur - Senior Vice President, Global Performance and Growth Revenue - leading a newly centralized global hub focused on supporting and scaling performance-based and DIY customers.

09:12 EDT Scilex completes enrollment in Phase 2 study of SP-103 - Scilex, a majority-owned subsidiary of Sorrento Therapeutics, announced complete enrollment in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 5.4% triple strength formulation for ZTlido, in subjects with acute LBP. "We are very pleased to have achieved this important milestone and would like to commend the experienced investigators and advisors of the SP-103 trial for their persistence and diligence in enrolling these patients. SP-103 has the potential to meet our core goal of developing leading pain management therapies to significantly improve the lives of patients with acute low back pain who are seeking new effective treatments," said Jaisim Shah, Chief Executive Officer and President of Scilex.

09:10 EDT Synchrony partners with CoFi for CareCredit payment solution - Synchrony announced a partnership with CoFi, a unique technology provider in the vision industry and multi-party patient payment platform. Through this partnership, Synchrony's CareCredit payment solution will now be integrated into the platform for the more than 2,000 ophthalmologists, optometrists, and surgery centers on CoFi's network. Through this partnership, Synchrony's CareCredit payment solution will now be integrated into the platform for the more than 2,000 ophthalmologists, optometrists, and surgery centers on CoFi's network, allowing patients the ability to use a CareCredit credit card to finance their consolidated care costs. CoFi launched its payment software in March 2021 with the ability to facilitate convenient, compliant payments directly to multiple parties when patients pay with a card or check.

09:08 EDT Teck Resources, CPKC announce long-term rail agreement - Canadian Pacific Kansas City (CP), CPKC, and Teck Resources Limited (TECK) announced that CPKC and Teck Coal Limited have entered into a long-term rail agreement for the transportation of steelmaking coal from Teck's four operations in southeastern B.C. The agreement builds on existing services in place and runs until the end of 2026. In support of building green transportation corridors and as a shared commitment to sustainability, CPKC and Teck intend to collaboratively develop a unique pilot program that integrates the use of CPKC's hydrogen locomotives into Teck's steelmaking coal supply chain. It is anticipated that this effort will reduce greenhouse gas emissions, with testing commencing in early 2024. "This collaboration with CPKC to pioneer hydrogen locomotive technology supports our climate action strategy and our objective of achieving net zero by 2050," said Jonathan Price, CEO, Teck. "The agreement complements our Neptune Terminals investment and other secured West Coast port capacity to support the efficient movement of our high-quality Canadian steelmaking coal to our global customers."

09:07 EDT Atlas Air announces Michael Steen to become CEO - Atlas Air Worldwide announced that Michael Steen, Executive Vice President and Chief Commercial Officer of Atlas, has been appointed Chief Executive Officer, CEO, of the Company, in line with the Company's long-term succession plan, effective June 15, 2023. Steen succeeds John Dietrich, who is retiring from the Company after nearly 25 years. Additionally, the company announced that Spencer Schwartz, Executive Vice President and Chief Financial Officer, CFO, is retiring from his role, effective June 15, 2023. Steen has more than 30 years of experience in aviation and logistics, including 16 years of executive leadership experience with Atlas.

09:05 EDT LPL Financial: Landmark Capital joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Thomas Reynolds, CFP and Kathleen Gfrorer, CFP of Landmark Capital, Inc. have joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported having served approximately $400 million in advisory, brokerage and retirement plan assets*, and join LPL from Securities America, now part of the Advisor Group network of broker-dealers. The team will shut down its own RIA to join LPL's corporate RIA to manage compliance, improve operations and provide an enhanced client experience.

09:04 EDT PBF Energy CEO Tom Nimbley to step down, Matthew Lucey to succeed - The Board of Directors of PBF Energy has named its current President, Matthew Lucey, as President and CEO and appointed him to the Board, effective July 1. Lucey will succeed current CEO Tom Nimbley, who will continue as Executive Chairman of the Board of Directors. Lucey joined PBF Energy's predecessor company at its formation in 2008, serving as the company's first CFO until 2014, when he became Executive Vice President. He has been President of the company since 2015, in charge of day-to-day operations and strategic projects. Prior to his tenure at PBF Energy, Lucey worked in private equity specializing in several sectors of the broader energy industry from 2001 to 2008. Before that, he spent six years in the banking industry.

09:04 EDT Arthur J. Gallagher acquires Leavitt Insurance Services of Los Angeles - Arthur J. Gallagher acquired Woodland Hills, California-based Leavitt Insurance Services of Los Angeles. Terms of the transaction were not disclosed. Leavitt offers commercial property/casualty insurance as well as employee benefits consulting to clients in the Southwest US. Teri Frankel, Kenneth Blaich and their team will remain in their current location under the direction of Scott Firestone, head of Gallagher's Southwest region retail property/casualty brokerage operations, and Charlie Isaacs, head of Gallagher's West region employee benefits consulting operations.

09:03 EDT Canadian Pacific Kansas City and Teck Resources sign long-term rail agreement - Canadian Pacific Kansas City (CP) and Teck Resources' (TECK)Teck Coal have entered into a long-term rail agreement for the transportation of steelmaking coal from Teck's four operations in southeastern B.C. The agreement builds on existing services in place and runs until the end of 2026. CPKC and Teck intend to collaboratively develop a pilot program that integrates the use of CPKC's hydrogen locomotives into Teck's steelmaking coal supply chain. It is anticipated that this effort will reduce greenhouse gas emissions, with testing commencing in early 2024.

09:00 EDT Quanta Services selected for SunZia transmission and SunZia wind projects - Quanta Services announced that it has been selected by Pattern Energy Group to provide comprehensive infrastructure solutions for the SunZia Transmission and SunZia Wind projects, which together represent the largest clean energy infrastructure project in United States history. Demonstrating the Power of One and its substantial scope and scale, Quanta will leverage the capabilities of multiple operating companies to execute these projects for Pattern Energy. Once completed, these projects will generate and transmit a significant amount of abundant wind energy from New Mexico to consumers in the western United States.

08:57 EDT TechPrecision announces uplisting to Nasdaq Capital Market - /TechPrecision announced that its shares of common stock have been approved for listing on The Nasdaq Capital Market. Trading on the exchange will commence effective with the open of business on Friday, May 5, 2023, under TechPrecision's current ticker symbol, "TPCS." The Company's common stock will continue to be eligible to trade on the OTCQB Market until the close of the market on May 4, 2023.

08:56 EDT Peloton sees tailwind from inventory to continue to moderate in FY24, says CFO

08:54 EDT Immunic reports data from study of IMU-856 in patients with celiac disease - Immunic announced positive results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease. The company believes that this data set provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture. Of particular interest, during the course of the trial, two IMU-856 treated patients demonstrated a 1-category improvement in Q-Marsh histology scores despite 15 consecutive days of exposure to gluten challenge. No analogous improvement was seen with placebo treatment.

08:54 EDT BTU Metals announces shareholder approval of agreement with Kinross Gold - BTU METALS announced the Company has received shareholder approval, via a Special Meeting, of an option agreement with Kinross Gold Corporation that will strengthen the exploration effort on the significant properties of BTU in the Great Bear gold area southeast of the main Red Lake Gold camp area of northwestern Ontario. The Dixie Halo Project is located adjacent to Kinross's Great Bear project that Kinross, on February 13, 2023, headlined in a press release: "Kinross announces robust initial mineral resource of 2.7 Moz. indicated and 2.3 Moz. inferred for Great Bear project". On February 22, 2023, BTU entered into an option agreement pursuant to which BTU granted an option to Kinross to acquire an undivided 70% interest in and to 757 mining claims covering approximately 16,410 hectares of land, located in the Kenora District of Ontario. During the term of the Option Agreement, Great Bear Resources will be the operator of the Optioned Properties.

08:52 EDT Peloton sees Q4 gross margin up 41% q/q driven by shift to subscription revenue

08:50 EDT Omniq's AI-based border safety system enhances with real-time anomaly detection - OMNIQ announced that its AI based Border Safety System has been enhanced with real-time anomaly detection. The technology allows for identification of unusual acceleration of vehicle speeds in high-risk areas, enabling authorities to respond immediately to potential threats. "OmniQ has been a vital part of border protection, successfully helping countries keep their borders and people safe," said Shai Lustgarten, CEO of OmniQ. "At the request of our customers, we have developed this proprietary, first-of-its-kind acceleration technology internally. With this technology now completed and deployed in one of the world's most sensitive areas, we anticipate continued success". This technology has been successfully deployed in a high-risk area and is already providing authorities with real-time alerts to potential threats. The system is designed to be scalable and adaptable to various border protection scenarios. Lustgarten concluded "We are excited to introduce this breakthrough technology to our customers and partners in the border protection industry. Our team has worked tirelessly to create a system that is highly effective and easy to use. We believe this technology will make a significant impact in the fight against crime and terrorism."

08:49 EDT Inotiv expands safety pharmacology offering, includes cardiopulmonary telemetry - Inotiv announced the expansion of the Company's safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in cynomolgus macaques. Offered through Inotiv's Discovery and Safety Assessment business, telemetry allows for the continuous observation of ECG, respiratory rate and volume, blood pressure and other cardiovascular parameters during preclinical safety studies. "The ICH S6 regulatory guidance on Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals indicates that safety pharmacology studies should be completed to reveal any test article related functional effects on the major organ systems including cardiovascular, respiratory, and central nervous system," said Tyler Speece, Director of Safety Pharmacology at Inotiv. "The cynomolgus macaque is frequently the only pharmacologically relevant species for the testing of biologics due to their anatomic and physiologic similarities to humans."

08:47 EDT Evoke Pharma announces data comparing GIMOTI to oral Metoclopramide - Evoke Pharma announced that the abstract entitled "Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide" will be presented at Digestive Disease Week 2023 taking place from May 6-9, 2023 at the McCormick Place, Chicago. David C. Kunkel, MD, Gastroenterologist and Associate Professor of Medicine at University of California San Diego Health, will deliver an oral presentation of the abstract in the AGA Clinical Practice Section Distinguished Abstract Plenary Session at DDW on Tuesday, May 9th at 8:20 AM CDT. The oral presentation will focus on the impact of GIMOTI to reduce healthcare resources across several settings, such as physician's offices visits, emergency room visits, and inpatient and outpatient hospital stays from a retrospective analysis of 514 diabetic gastroparesis patients compared those receiving oral metoclopramide. GIMOTI is the first and only FDA-approved nasal formulation of metoclopramide commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent DGP. By bypassing the stomach and being directly absorbed in the bloodstream, GIMOTI may provide relief to patients experiencing acute and recurrent flares, especially nausea, vomiting and abdominal pain, which can result in increased visits to their doctors and reliance on costly emergent care .

08:46 EDT Cellectar Biosciences expects cash to fund operations into Q4 - As of March 31, 2023, the company had cash and cash equivalents of $12.7 million, compared to $19.9 million as of December 31, 2023. Net cash used in operating activities during the three months ended March 31, 2023 was approximately $7.2 million. The company believes its cash on hand is adequate to fund budgeted operations into the fourth quarter of 2023.

08:45 EDT Huntington Bancshares raises prime rate to 8.25% from 8.00%, effective May 4

08:43 EDT Veru reaches agreement with FDA on confirmatory Phase 3 trial for sabizabulin - Veru announced that in an April 27, 2023 meeting, the Company and FDA reached agreement on the design of the Phase 3 confirmatory COVID-19 clinical trial to evaluate sabizabulin treatment in hospitalized moderate to severe COVID-19 patients who are at high risk for acute respiratory distress syndrome, ARDS, and the path forward to submit a new Emergency Use Authorization, EUA, application and/or New Drug Application, NDA. Based on the FDA's positive feedback on the confirmatory Phase 3 clinical study design and program, the Company anticipates initiating the clinical study in the second half of 2023. Highlights from the April 27th FDA meeting: FDA agreed to a confirmatory Phase 3, randomized, multicenter, global, efficacy and safety study of sabizabulin 9mg oral daily dose plus standard of care treatment versus placebo plus standard of care treatment in 408 hospitalized adult patients with moderate to severe SARS-CoV-2 infection who are at high risk for ARDS: Indication for sabizabulin has been expanded to include all hospitalized moderate to severe COVID-19 patients: WHO-4, WHO-5, or WHO-6 without a requirement to have a comorbidity. Endpoints: Primary efficacy endpoint is all-cause mortality at Day 60; Secondary endpoints include Days in the hospital, Days in the ICU, Days on mechanical ventilation, and proportion of patients alive without respiratory failure; Exploratory endpoint is the presence of long COVID-19 symptoms at Day 180. In order to get a potentially efficacious drug to patients in an efficient time frame, two interim efficacy analyses are planned: the first planned interim analysis is expected to occur when 50% of patients have completed the Day 60 primary efficacy endpoint as recommended by FDA, and the second planned interim analysis is expected to occur when 71% of patients have completed the Day 60 primary efficacy endpoint. If either planned interim efficacy analysis meets statistical significance criteria, the trial could be stopped. Should the pre-specified primary efficacy endpoint analysis demonstrate a statistically significant effect on all-cause mortality favoring sabizabulin - the Company may consider a new request for an EUA and/or a submission of an NDA, as the Company would have two adequate and well controlled trials demonstrating efficacy. As the program has FDA Fast Track designation, a rolling NDA submission is a possibility for sabizabulin. The Phase 3 confirmatory COVID-19 clinical trial is expected to begin enrolling in the second half of 2023, and the first planned interim efficacy analysis is anticipated to be conducted in 2024.

08:43 EDT ReWalk to provide first U.S. demonstration of stairs-enabled exoskeleton - ReWalk Robotics announced the first public U.S. demonstration of its innovative stairs-enabled exoskeleton at the upcoming Abilities Expo New York from Friday, May 5th to Sunday, May 7th. The Abilities Expo, to be held at the New Jersey Convention and Expo Center, is open to the public and free to attend. ReWalk Robotics will feature demonstrations with ReWalk users at Booth #738 at 1 p.m. and 3 p.m. daily to showcase how this new technology enables individuals with spinal cord injury to walk in real-world environments, including locations with stairs or curbs.

08:41 EDT ABVC BioPharma receives U.S. patent certificate for PDC-1421 - ABVC Biopharma announced it received a US patent certificate, US 11,554,154 B2, for PDC-1421, for the treatment of Major Depressive Disorder on April 25, 2023. The patent application was submitted to the US Patent and Trademark Office on July 22, 2020, under the title of "Polygala Extract for the Treatment of Major Depressive Disorder." The invention relates to a method for treating Major Depressive Disorder by orally administering a composition containing a Radix Polygalae extract. PDC-1421 is a drug product of ABV-1504 that can be prepared into a gelatin capsule for oral administration. The composition can be administered chronically over at least 25 days; the daily dose can be administered once per day, twice per day, or three times per day, wherein each dose is 380 - 760 mg of the botanical extraction. ABV-1504 is a botanical-based Norepinephrine Transporter inhibitor that has completed Phase II clinical studies, with plans to initiate an End of Phase II meeting with the FDA shortly. The patent was also submitted for Patent Cooperation Treaty and subsequently filed in several countries, including the European Union, China, Japan in 2022.

08:41 EDT Peloton having success with sale of PCR bikes - The company said: "We are having success with the sale of our PCR bikes which we launched in December of 2022, following several successful tests in FY23. The program currently includes Bike and Bike+. We're exploring whether to extend the program to Tread and Row later this year. We sold a total of 7 thousand PCR bikes in Q3."

08:39 EDT Verb Technology regains compliance with Nasdaq minimum bid price requirement - Verb Technology announced that it has regained compliance with Nasdaq's listing requirements. The Company received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

08:38 EDT Triumph Financial announces $50M share repurchase authorization - Triumph Financial has completed its accelerated share repurchase transaction on April 28, 2023. On February 1, 2023, the Company entered into an accelerated share repurchase agreement under which it repurchased 1,209,327 shares of its common stock for a total cost of $70 million. In connection with the completion of the accelerated share repurchase transaction, on May 4, 2023, the Company's board of directors authorized a new share repurchase program whereby the Company may repurchase up to an additional $50 million of its outstanding common stock. The Company may repurchase shares from time to time in open market transactions or through privately negotiated transactions at the Company's discretion. The amount, timing, and nature of any share repurchases will be based on a variety of factors, including the trading price of the Company's common stock, applicable securities laws restrictions, regulatory limitations, as well as market and economic factors. The repurchase program is authorized for a period of up to one year and does not require the Company to repurchase any specific number of shares. At the Company's discretion, the repurchase program may be modified, suspended or discontinued at any time.

08:37 EDT Esperion retains Gibson Dunn to secure $300M payment from DSE - Esperion (ESPR) announced that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (DSNKY) and filed an amended complaint against DSE in the Southern District of New York. The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300 million milestone payment to Esperion upon regulatory approval. DSE recently stated it will not make the $300 million milestone payment that the contract requires. The amended complaint, filed by Gibson Dunn's Orin Snyder, one of the country's foremost trial lawyers, provides substantial new evidence demonstrating that DSE's repudiation of the agreement is wrong and in bad faith: The amended complaint establishes that the key term in the contract, "cardiovascular risk reduction," is unambiguous and is not limited to MACE-4 results, as DSE now says. The amended complaint includes previously undisclosed drafts of the parties' agreement in which Esperion specifically rejected DSE's proposal to limit "cardiovascular risk reduction" to MACE-4 results. The amended complaint makes clear that DSE is repudiating the agreement in a transparent attempt to drive down Esperion's stock price and pressure it to re-negotiate the parties' license agreement.

08:35 EDT Peloton 'in striking distance' of reaching cash flow positive - Comments taken from Q3 earnings conference call.

08:35 EDT eMagin demonstrates WUXGA display using dPd technology - eMagin Corporation announced the demonstration of a new 15,000 candela per square meter WUXGA display using its Direct Patterning Display technology that surpasses the previous record of 10,000 cd/m2 that eMagin set 18 months ago.

08:32 EDT MDU approves separation of Knife River - MDU Resources has approved the separation of the company's wholly owned construction materials subsidiary, Knife River Corporation, through a pro rata distribution of the outstanding shares of common stock of Knife River Holding Company, which is the newly formed parent company for Knife River Corporation. MDU Resources stockholders will retain their current shares of MDU Resources common stock and, on the distribution date, each MDU Resources stockholder will receive a distribution of one share of Knife River common stock for every four shares of MDU Resources common stock owned as of the record date. Knife River common stock is expected to be distributed at 11:59 p.m. EDT May 31, 2023, to MDU Resources stockholders of record as of 5 p.m. EDT on May 22, 2023, the record date for the distribution. The distribution of shares does not require stockholder approval and no action is required by MDU Resources stockholders to receive the shares of Knife River common stock, or cash in lieu of fractional shares. The distribution is expected to be tax free for MDU Resources stockholders for U.S. federal income tax purposes. Following the separation, MDU Resources and Knife River will be independent, publicly traded companies with distinct investment identities, business operations, customers and geographic markets.

08:27 EDT Fastenal reports April sales up 2.7% to $586.18M - Fastenal reported April sales of $586.178M versus $570.760M in the same month of last year. Fastenal reported April daily sales of $29.31M, up 7.8% versus 2022.

08:26 EDT Carl Icahn sends open letter to Illumina shareholders - Carl Icahn released an open letter to the shareholders of Illumina. The letter says in part: "We have detailed many abuses by Illumina's management and board of directors in our past letters that need not be repeated in this letter (otherwise, we would never get to the point of this letter - since the list of abuses is egregiously long). This letter instead focuses on our go-forward plan and what our nominees would expect to do as board members if elected. It is important to note a few things. We are seeking three board seats on a board of nine directors (soon to be eleven, thanks to the deplorable decision by Illumina to disenfranchise its shareholders by adding two new directors after the annual meeting). Any actions that our nominees propose as board members will obviously need to garner the support of a majority of the board. After the proxy contest is over, we pride ourselves on working with boards in a collegial and constructive manner, asking the tough and sometimes uncomfortable questions and seeking out information that management might be obfuscating. When we show up in a boardroom we never know exactly what we will find and how we will be greeted by the other board members. There very well could be current Illumina board members who did not want to acquire GRAIL over the explicit prohibition of regulators, who don't want to fight the two most powerful antitrust bodies in the world, and who believe that CEO Francis deSouza and Chair John Thompson are not qualified to lead Illumina. There might be board members that are sympathetic to our beliefs but are intimidated to speak up (as it is a hard thing to do). We are prepared to be those voices in the room. Secondly, we do not believe that board members should micromanage CEOs or be intimately involved in executing the company's strategy. We believe that the primary jobs of board members are to hire/fire the CEO, hold the CEO and team accountable to a plan, help guide strategy, and prevent companies from avoidable calamity (for example: closing an acquisition over the explicit prohibition of regulators, subjecting the company to $500 million in fines, incurring $800 million of annual operating losses, breaking all regulatory trust, etc.). Now that our framework has been established, we believe Illumina can become the great company it once was by following a few important steps: (1) separate from GRAIL as quickly as possible by working with the antitrust agencies (not fighting them tooth and nail); (2) replace CEO Francis deSouza; and (3) focus on Core Illumina and reinvigorating its historic financial profile of double digit revenue growth and margin improvement potential." Reference Link

08:23 EDT Zions Bancorp Chairman, CFO each buy 20,000 shares - Zions Bancorp Chairman of the Board Harris Simmons bought 20,000 shares at an average price of $24.16 in transactions valued at $483,200 on May 3, while CFO Paul Burdiss bought 20,000 shares at an average price of $27.42 in transactions valued at $548,436 on May 1, as disclosed in regulatory filings.

08:23 EDT Silver Tiger Metals announces drill results from Sulphide Zone - Silver Tiger Metals has intersected 1,581.4 g/t total silver equivalent over 6.3 meters in the Sulphide Zone in Drill Hole ET-23-457 from 445.0 meters to 451.3 meters, consisting of 1,100.1 g/t silver, 0.15 g/t gold, 0.87% copper, 5.10% lead and 8.01% zinc within 38.7 meters grading 438.9 g/t total silver equivalent from 441.0 meters to 479.7 meters consisting of 297.5 g/t silver, 0.11 g/t gold, 0.28% copper, 1.42% lead and 2.19% zinc in the Sulphide Zone. Highlights from the on-going drilling program include the following: Hole ET-23-457: 3.4 meters grading 1,948.8 g/t total silver equivalent from 445.0 meters to 448.4 meters, consisting of 1,245.7 g/t silver, 0.13 g/t gold, 1.00% copper, 6.38% lead and 13.43% zinc within 38.7 meters grading 438.9 g/t total silver equivalent from 441.0 meters to 479.7 meters consisting of 297.5 g/t silver, 0.11 g/t gold, 0.28% copper, 1.42% lead and 2.19% zinc in the Sulphide Zone.

08:22 EDT Signal Gold announces non-brokered private placement for up to $7M - Signal Gold proposes to complete a non-brokered private placement to raise gross proceeds of up to $7,000,000. The Offering will consist of up to 16,666,667 units of the Company at a price of $0.30 per Unit, and up to 5,555,556 "flow-through" units of the Company at a price of $0.36 per FT Unit. Each FT Unit will consist of one common share to be issued as a "flow-through share" as defined in subsection 66 of the Income Tax Act and one-half of one common share purchase warrant to be issued on a non-flow-through basis. Each Unit will consist of one common share and one-half of one Warrant. Each Warrant will entitle the holder thereof to purchase one common share of the Company at a price of $0.45 for a period of 18 months following the closing date of the Offering. The Warrants will contain an acceleration clause whereby, after the expiration of the statutory hold period, if the common shares of the Company trade at a volume weighted average price of $0.75 or more for 10 consecutive trading days, the Company will have the right to accelerate the exercise period to a period ending at least 30 days from the date that notice of such acceleration is provided to the holders of the Warrants. It is expected that the gross proceeds from the Offering will be primarily used to advance activities for development and exploration at the Goldboro Gold Project in Nova Scotia and for working capital and general corporate purposes.

08:21 EDT Xwell names Valerie Lightfoot as CFO - XWELL announced that Valerie Lightfoot has been named Chief Financial Officer, CFO, effective June 12, 2023. Lightfoot joins XWELL with over 25 years of financial leadership experience. During her career, she has helped companies successfully execute organic growth initiatives, integrate acquisitions as well as implement process improvements and achieve improving cashflow. Lightfoot succeeds Omar Haynes, who has been diligently serving as Interim Chief Financial Officer since June 2022. Haynes will remain with the Company and resume his former role at Vice President, Finance and Treasury. Prior to joining XWELL, Lightfoot served as CFO for Green River Spirits-a leading manufacturer of spirit brands and home to one of Kentucky's oldest whiskey distilleries, until it was acquired in 2022.

08:19 EDT Enphase Energy launches new IQ8 microinverters in Poland - Enphase Energy announced the launch of IQ8 Microinverters, with peak output AC power of 384 W, in Poland to support newer high-powered solar modules. The new IQ8 Microinverters are designed to maximize energy production and can manage a continuous DC current of 14 amperes, supporting higher powered solar modules through increased energy harvesting. All IQ8 Microinverters activated in Poland come with a 25-year warranty from Enphase. "We're pleased to continue the expansion of Enphase product offerings across Europe and work with leading installers in Poland to provide cutting-edge technology to homeowners across the region," said Marco Krapels, vice president of international sales at Enphase Energy. "The latest line of IQ8 products allows Enphase product installers to continue offering the highest quality service by providing homeowners with a solar energy system capable of supporting the most powerful solar modules on the market."

08:17 EDT Humacyte's HAV receives FDA's RMAT designation - Humacyte has been recently granted the U.S. Food and Drug Administration's, FDA, Regenerative Medicine Advanced Therapy, RMAT, designation for its Human Acellular Vesse for urgent arterial repair following extremity vascular trauma. The FDA's RMAT designation is for breakthrough therapy of regenerative medicine. The designation allows for more interactions with the FDA and expedited development and review of regenerative medicine products within the U.S., including the potential for priority review process for a Biologics License Application (BLA). This is the second RMAT designation granted by the FDA for Humacyte's HAV, in addition to a previous RMAT granted for arteriovenous (AV) access in hemodialysis. "We are delighted to receive our second RMAT designation from the Food and Drug Administration," said Dr. Cindy Cao, Chief Regulatory Officer at Humacyte. "The RMAT designation for the HAV in our lead indication of vascular trauma is an important milestone. This designation will further enhance our communication with the FDA and will provide us with a higher likelihood for an expedited review of our planned upcoming BLA filing." Humacyte is nearing the completion of enrollment in its Phase 2/3 V005 clinical trial of the HAV in the repair of civilian vascular trauma, a study that is being conducted at Level 1 Trauma Centers in the U.S. and Israel. Currently, a total of 66 patients have received the HAV in the V005 trial, including 49 patients comprising the primary endpoint population. Humacyte plans to file a BLA with the FDA later in 2023.

08:14 EDT Lightbridge joins two public-private nuclear power groups - Lightbridge Corporation announced that the Company has joined two important Public-Private nuclear power groups: the U.S. Department of Energy's High-Assay, Low-Enriched Uranium Consortium, and the U.S. Department of Commerce International Trade Administration's Small Modular Reactor Working Group. In December 2022, the DOE announced the creation of a HALEU Consortium to support the establishment of domestic HALEU infrastructure pursuant to the Energy Act of 2020. The purpose of the Consortium is to provide the Secretary of Energy with HALEU demand estimates for domestic commercial use, purchase HALEU made available to members for commercial use, carry out demonstration projects using HALEU, and identify actionable opportunities to improve the reliability of the HALEU supply chain. The U.S. Department of Commerce International Trade Administration's SMR Working Group supports the deployment and export of U.S. SMRs in European markets while ensuring safety, security, and nonproliferation. The SMR Working Group aims to expedite SMR deployment by facilitating collaboration between the U.S. industry, government, and European partners. Through quarterly meetings, members gain sector knowledge and networking opportunities with prospective European customers and government officials, ultimately positioning U.S. companies for success in the European SMR market.

08:13 EDT BorgWarner to supply eMotors for automotive manufacturer in China - BorgWarner has been selected to provide HVH eMotors to a leading automotive manufacturer in China. The eMotors will be used in the Chinese automaker's DHT and REEV, with mass production expected to start in August 2023 in Tianjin. This HVH motor uses a compact design with an optimized conductor-winding structure that shortens the motor, making it suitable for smaller installation space, and improves efficiency on major driving cycles.

08:12 EDT Alpha Teknova announces time change for Q1 results - Alpha Teknova announced that the Company has changed the timing of its previously announced first quarter 2023 financial results webcast and conference call to 5:30 p.m. Eastern Time on Wednesday, May 10, 2023.

08:11 EDT BorgWarner to supply battery packs for electric buses - BorgWarner has been selected by a global power technology leader to supply battery packs for a series of electric buses. BorgWarner will provide a pair of standardized ultra-high energy packs and a battery management system that the company will integrate into its electrification package for each vehicle. The package will be sold to an electric bus manufacturer in Georgia. BorgWarner's battery packs are safe and reliable containing state-of-the-art safety features including current overcharge protection, cell-level passive propagation resistance, and electrical disconnection at the individual cell wire bonds that satisfy the industry's strict electric vehicle battery safety standards. Additionally, the 98 kWh packs offer active cooling and deliver industry-leading energy density of 274 Wh/liter and 177 Wh/kilogram. Production of the battery packs began in March 2023.

08:10 EDT Cerence signs win-back with luxury automaker - Cerence announced a significant competitive win-back with one of the world's top international luxury automakers. The automaker awarded Cerence its cloud business in North America; with this win, Cerence adds an additional region to its full-stack embedded and cloud in-car assistant program with the global automaker. With this new program win, Cerence will add cloud-based voice recognition and natural language understanding in languages for Canada, Mexico, and the US to its already extensive in-car assistant support for the automaker. Beyond the new cloud-based technology, the automaker will also leverage dedicated cloud content domains from Cerence, including weather, sports, navigation, stocks, general knowledge, and more, improving drivers' access to much-needed information on the road. The automaker will also deploy Cerence Tour Guide, a new AI-powered application for automotive assistants that brings professional, guided tour content directly into the car, further enhancing the experience for the drivers.

08:05 EDT Green Plains announces offer to acquire Green Plains Partners at $13.08 p/s - Green Plains (GPRE) announced it has submitted a proposal to the Board of Directors of Green Plains Holdings, the general partner of Green Plains Partners (GPP) to acquire all of the publicly held common units of the Partnership not already owned by Green Plains in a stock-for-unit exchange. Subject to negotiation and execution of a definitive agreement, Green Plains Inc. is proposing consideration of 0.3913 shares of Green Plains common stock for each outstanding publicly held Partnership common unit. The proposed consideration represents a value of $13.08 per common unit of the Partnership based on the closing price of Green Plains Inc.'s common stock and the Partnership's common units as of May 3. The proposed transaction is subject to the negotiation and execution of a definitive agreement and approval of such definitive agreement and transactions contemplated thereunder by the board of directors of Green Plains Inc., the board of directors of Green Plains Holdings LLC, and its conflicts committee. The consummation of the proposed transaction would be subject to customary closing conditions. There can be no assurance that any such approvals will be forthcoming, that a definitive agreement will be executed, or that any transaction will be consummated.

08:04 EDT Mullen Automotive readies for commercial launches, announces customer pricing - Mullen Automotive announces customer vehicle pricing for the Mullen ONE, Class 1 EV Cargo Van and Mullen THREE, Class 3 EV Cab Chassis Truck. "As more fleets focus on their sustainability goals addressing climate change, the net price points of our Mullen commercial products make this an easy choice and help accelerate their transition to electric," said David Michery, CEO and chairman of Mullen Automotive. "With both vehicles qualifying for the $7,500 federal tax credit, their Class 1 EV Cargo Van acquisition cost will reduce to $27,000 and Class 3 EV Cab Chassis Truck will reduce to $61,000." Mullen ONE, Class 1 Urban Delivery EV Cargo VAN; Starting MSRP: $34,500; Available federal tax credit: $7,500; Vehicle net price: $27,000. The Mullen ONE is anticipated to be the first EV cargo van for sale in the U.S. market in the Class 1 commercial vehicle segment. This van was designed for last mile delivery, with best-in-class cargo volume, payload, and turning diameter to easily navigate through narrow urban streets and residential roads. Mullen THREE, Class 3 Urban Utility EV Cab Chassis Truck; Starting MSRP: $68,500; Available tax credit: $7,500; Vehicle net price: $61,000. There are also various state incentives, such as the California HVIP program, which offers up to $45,000 incentive for commercial Class 3 products like the Mullen THREE EV Cab Chassis Truck. The Mullen THREE is an efficient Class 3 low cab forward EV truck featuring a tight turning diameter of 38 feet and excellent visibility for superior maneuverability on narrow city streets. This versatile chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and over 5,800 pounds of payload. In addition, the design of the LCF chassis allows more cargo volume within a given overall length. To-date, 19 EV Cargo vans have been delivered with 20 additional deliveries targeted for May 2023. Additionally, the Company is also anticipating a purchase order for 200 Class 1 EV vans anticipated in May 2023. Recently, a 1,000-unit purchase order, valued at $63M, for Class 3 EV Cab Chassis Trucks from Randy Marion Automotive Group was announced on May 2, 2023. Production is planned to begin in August 2023 and final deliveries completed by Q1 2024. All commercial vehicles are produced in Tunica, Mississippi.

08:04 EDT Protara Therapeutics expects cash to fund operations into 2025 - Continue to expect cash, cash equivalents and investments of $90M as of March 31, 2023 to fund operations into 2025

07:59 EDT Movella introduces MTi-320 high performance AHT - Movella Holdings introduced the MTi-320, a high-performance Active Heading Tracker with a small form factor designed for integration to any system requiring accurate heading tracking, such as warehouse and last-mile delivery robotics and autonomous vehicles. The MTi-320 with the high performance Xsens sensor fusion algorithm accurately tracks changes in heading where alternative solutions have trouble with accurately integrating of the gyroscope data or distortion caused by external magnetic fields. Under such environments, the MTi-320 provides stable and robust heading tracking. With the ability to track heading changes up to 2000 dps, less than 0.5W power consumption and a small form factor of 28 x 31.5 x 13mm, the MTi-320 is an ideal solution for many robotics and autonomous vehicle applications.

07:53 EDT Holly Energy Partners confirms proposal letter from HF Sinclair - Holly Energy Partners (HEP) announced that it has received a non-binding proposal letter from HF Sinclair (DINO) to acquire all of the outstanding common units of HEP not beneficially owned by HF Sinclair or its affiliates in exchange for shares of common stock, par value $0.01 per share, of HF Sinclair. Under the proposal, HF Sinclair proposes to effect the transaction at a fixed exchange ratio of 0.3714 newly issued shares of Common Stock per each publicly held Common Unit, which was derived using the 30-day volume weighted average prices for each security as of market close on May 3, 2023.

07:51 EDT OverActive Media signs sponsorship agreements with AMD, LG UltraGear - OverActive Media (OAMCF) announced multiple sponsorships and renewals. The Company has successfully secured new agreements with AMD (AMD) and LG UltraGear and renewed relationships with Scuf Gaming, SCUF, and Nielsen Sports. "We continue to build business momentum with the addition of AMD and LG UltraGear, and our renewal with SCUF. Each of these brands are best-in-class in their respective spaces and offer relevant and engaging opportunities and benefits for our audiences," said Tyler Keenan, Senior Vice-President, Partnerships & Revenue. "In addition to our ability to reach esports and gaming fans, Nielsen Sports will elevate our partner offering through in-depth data and analytics, which we can now implement in Spain." The partnership highlights include the following: AMD will collaborate with Toronto Ultra and Toronto Defiant for content and activation opportunities. Through its partnership specific to Toronto Ultra, LG UltraGear joined as presenting partner for the Call of Duty League Major IV tournament and qualifiers. SCUF has been a partner of OverActive since 2020. OverActive has expanded its relationship with Nielsen Sports to now include the Company's European-based brand, MAD Lions.

07:48 EDT Marathon Gold provides Q1 construction progress report - Marathon Gold Corporation provides an update on first quarter construction progress at its 100% owned Valentine Gold Project located in central Newfoundland. Matt Manson, President and CEO, commented: "The first quarter of 2023 represented the first full quarter of principal construction at the Valentine Gold Project. We are pleased with the progress we have made to date, in particular with mining productivity at the Leprechaun pit and the progress of earthworks at the future process plant site. At time of writing, we are preparing for the full occupation of our new permanent camp and the commencement of concrete foundation work at the mill. This is the first year that we have worked at Valentine through the spring thaw, and we are grateful to our staff and contractors for their patience and collaboration as we worked through the short-term logistical challenges that this entailed. As we move into the warmer weather months, we are pleased to report that construction is tracking the overall project development plan well."

07:46 EDT Rogers Communications lowers price of data on 5G unlimited plan - Rogers Communications Inc. announced it will make 5G more accessible to more Canadians. The company has reduced the price per gigabyte of data by 50% on its most-chosen plan, has lowered its 5G entry price, and will provide all Rogers 4G wireless customers with access to the 5G network at no cost. Starting today, Rogers is offering new 5G wireless plans and bundles that bring more value and choice to Canadians: Double the ultra speed data on its popular $85/month unlimited plan; customers can now access 50GB of the fastest Rogers 5G speeds for the price of the previous 25GB plan; Bundled with residential services, customers can now get a 5G wireless plan starting at $55 per month, priced 35% lower than the previous 5G entry plan on Canada's best network; More choices available to more customers with new 5G plans for newcomers to Canada, parents of kids and teens getting their first phone, and individuals aged 55+; Over the coming months, all Rogers wireless customers with voice and data plans will be proactively provided with access to the Rogers 5G network, at no extra charge.

07:45 EDT First Horizon sinks 40% to $9 after termination of TD merger agreement

07:45 EDT Emerita Resources reports assay results from drilling at La Romanera deposit - Emerita Resources announced additional assay results from the ongoing delineation drilling program at La Romanera Deposit, part of Emerita's wholly owned Iberian Belt West Project. These results will be included in the upcoming maiden NI 43-101 compliant mineral resource estimate. Assays from 10 additional drill holes from La Romanera deposit have been received. IBW hosts three previously identified massive sulphide deposits: La Infanta, La Romanera and El Cura. All deposits are open for expansion along strike and at depth. Joaquin Merino, P.Geo., President of Emerita stated, "These holes are being incorporated into the block model for the forthcoming MRE. Meetings are occurring this week with Wardell Armstrong International, who has been engaged to complete the MRE, to review and refine the block model as we approach completion. Assay data for the remaining few drill holes is being incorporated as they are received." La Romanera assay results include holes LR085, LR090, LR096, LR112, LR114, LR137, LR140, LR142, LR144, and LR145 and are reported below. These holes are distributed broadly across the deposit between +100 and -350 m elevation. Drill hole intercepts below 250 m depth intercepted both the Upper and Lower Lenses. In some cases, the width of the lenses exceeds 30 meters and returned high grades in base metals as well as gold and silver. Drill hole intercepts in the upper part of the deposit intercepted both the Upper and Lower Lenses. The Upper Lens is characterized by high grade in base metals, gold and silver over narrow widths. The Lower Lens presents moderate widths in base metal grades and moderate to high grades in gold and silver.

07:44 EDT Enthusiast Gaming receives 180-day extension to NASDAQ minimum bid price - Enthusiast Gaming Holdings announced that on May 3, 2023, the Listing Qualifications department of the Nasdaq Stock Market LLC approved the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) The Company now has until October 30, 2023 to regain compliance. If at any time prior to October 30, 2023, the bid price of the Company's common shares closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule. In connection with the Extension, the Company has transferred the listing of the Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on May 4, 2023. Neither the Company's operations nor the Company's TSX listing are affected by the transfer of the Company's listing to the Nasdaq Capital Market. The Shares will continue to trade without interruption under the symbol "EGLX." The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Select Market, and companies on the Nasdaq Capital Market must meet certain financial and corporate governance requirements to qualify for continued listing.

07:43 EDT Village Farms announces launch of cannabis products in Germany - Village Farms International announced the launch in Germany of cannabis products grown by its Canadian Cannabis business. The German launch is in partnership with IUVO Therapeutics, an importer, marketer and distributor of medical cannabis for the German market. IUVO expects Pure Sunfarms' Pink Kush to be available to German patients in the coming days.

07:41 EDT Intellia Therapeutics announces upcoming milestones - NTLA-2001 for ATTR amyloidosis: Submit an IND application in mid-2023 to enable inclusion of U.S. sites in a pivotal study of NTLA-2001 for patients with ATTR-CM. Present additional clinical data from the ongoing Phase 1 study of NTLA-2001 in 2023. Initiate a global pivotal NTLA-2001 trial for ATTR-CM by year-end 2023, subject to regulatory feedback. Prepare for a Phase 3 study of NTLA-2001 for the treatment of ATTRv-PN, including discussions with regulatory authorities. NTLA-2002 for HAE: Present additional clinical data from the ongoing first-in-human study of NTLA-2002 in 2023. Complete enrollment in the Phase 2 portion of the Phase 1/2 study in 2H 2023. AATD Franchise: Submit an IND or IND-equivalent application for NTLA-3001 for AATD-associated lung disease in 2H 2023. Complete IND-enabling activities for NTLA-2003 for AATD-associated liver disease by year-end 2023. Platform Innovation: Advance novel gene editing technologies, including DNA writing and delivery to other tissues outside of the liver.

07:40 EDT Constellation Energy reports Q1 adjusted EBITDA $658M - Q1 GAAP Net Income decreased to $96M from $106M GAAP Net Income in 1Q22. "We had a strong start to 2023, putting us in position to end the year comfortably in the top half of our guidance range and giving us confidence to raise our gross margin outlook for 2024," said Joe Dominguez, CEO. "Our performance was led by the Commercial team as customers came to us for help managing their energy needs in a time of volatile markets, a trend we think will continue to create value for the balance of 2023 and into 2024. Our clean generation fleet also performed well during the quarter, reliably delivering affordable, carbon-free energy to homes and businesses across the country." "We are returning significant value to our shareholders after doubling our dividend since last year and completing about a quarter of the $1B share repurchase program authorized in February," said Dan Eggers, CFO. "Our balance sheet remains a competitive advantage in the marketplace and is the foundation of our capital allocation strategy, which allows us to create compelling value for our shareholders."

07:39 EDT Selecta implements capital prioritization initiative, reduces headcount by 25% - Following a comprehensive review of its portfolio and capital resources, Selecta, in consultation with the Company's Board of Directors, plans to streamline operations and prioritize investments in select programs. As part of this initiative, the Company plans to: Advance SEL-212 in Patients with Chronic Refractory Gout in Partnership with Sobi. In March 2023, Selecta and its SEL-212 development partner, Sobi, reported positive Phase 3 data from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials. Both trials met their primary endpoint, and SEL-212 was observed to be safe and well-tolerated. A BLA submission remains on track for the first half of 2024. In June 2020, Sobi licensed SEL-212 from Selecta and is responsible for development, regulatory, and commercial activities in all markets outside of China. Prioritize Development of the Combination of ImmTOR and Company's Proprietary Treg-Selective IL-2. The combination of ImmTOR and IL-2 represents an evolution of Selecta's precision immune tolerance platform. The Company remains on track to initiate Investigational New Drug-enabling studies in 2023, while also exploring multiple autoimmune indications that may be suitable for study with ImmTOR-IL, with an initial focus on diseases of the liver. Develop SEL-018 IgG Protease for LOPD in Partnership with Astellas Gene Therapies. In January 2023, the Company announced an exclusive licensing and development agreement for IdeXork, a next-generation immunoglobulin G protease, to be developed for use with AT845, Astellas Gene Therapies' investigational adeno-associated virus-based treatment for Late-Onset Pompe disease in adults. Xork is designed to be differentiated by its low-cross reactivity to pre-existing antibodies in human serum, which the Company believes has the potential to expand access to life-changing gene therapies for more patients. Advance Gene Therapy Programs through Potential Partnerships. Selecta will pause further development of its wholly-owned gene therapy programs, including the ongoing Phase 1/2 clinical trial of SEL-302, an AAV gene therapy combined with ImmTOR for the treatment of methylmalonic acidemia. The Company is currently assessing ways to support further development of these programs through potential partnerships. Reduction in Force. The Company reduced its headcount by approximately 25% in order to align its workforce with its updated priorities. As a result of the reduction in force, the Company expects to incur a cash charge of approximately $1.0 million related to severance and benefit-related expenses.

07:32 EDT Shopify says 'will be smaller by about 20%' after today - Shopify Founder and CEO, Tobias Lutke, said in a message to the team that the company shared on its site: "We are changing the shape of Shopify significantly today to pay unshared attention to our mission. There are a number of consequences to this, and I don't want to bury the lede: after today Shopify will be smaller by about 20% and Flexport will buy Shopify Logistics; this means some of you will leave Shopify today. I recognize the crushing impact this decision has on some of you, and did not make this decision lightly. In the next 5 minutes you'll get a follow up that tells you if you are affected. There's no way to make this good news, but we designed a package that will attempt to make it the best possible version of a bad day. I've included details below on how we will support you... It's the right thing for Shopify but it negatively affects many team members who we admire and love working with. This is one of those times where both right and hard are true at the same time. My belief is that any enduring company makes a habit of doing the right thing, even if easy outs present themselves. Yet it doesn't get easier to make a decision like this, and I hope it never does." Reference Link

07:30 EDT Optinose announces FDA acceptance of sNDA for XHANCE - Optinose announced the U.S. Food and Drug Administration, FDA, accepted for review its supplemental new drug application, sNDA, requesting approval of XHANCE as a treatment for chronic rhinosinusitis. XHANCE nasal spray is a drug-device combination product that combines the most widely used nasal anti-inflammatory drug with the innovative Exhalation Delivery System, EDS. The EDS is designed to uniquely deliver drug high and deep into difficult-to-access sinuses and sinonasal drainage tracts. The sNDA submission is based on data from the two Phase 3 clinical trials in patients with chronic sinusitis from the ReOpen Program and has been assigned a Prescription Drug User Fee Act target goal date of December 16, 2023. "Chronic sinusitis is one of the top diagnoses made in adult outpatient visits, with approximately 10 million physician office visits coded annually, yet there is a high level of patient dissatisfaction and suffering and no FDA approved drug treatments except for patients who also have nasal polyps," stated Ramy Mahmoud, MD, MPH, CEO of Optinose. "We are excited to see our study data under FDA review as we believe the ReOpen trials found important benefits that XHANCE could offer to physicians and their patients as a first-ever drug approved to treat chronic rhinosinusitis."

07:28 EDT Nokia secures 5G RAN deal with Orange Jordan - Nokia has been selected by Orange Jordan to supply 5G Radio Access Network equipment throughout the Kingdom of Jordan, the company announced today. The deal will enable Orange Jordan to provide enhanced connectivity and capacity to its customers as well as to lay the foundations supporting the digital transformation of the country and economy. Nokia will supply 5G RAN equipment from its comprehensive AirScale portfolio powered by its energy-efficient ReefShark System on Chip technology and will replace Orange Jordan's entire existing RAN network. Orange Jordan aims to provide 5G services to 50 percent of the population within four years followed by five percent year-on-year growth. The deal includes the latest generation massive MIMO radios with support for high RF bandwidth as well as AirScale Baseband and Dual-band Remote Radio Head products. In addition, Nokia will supply its Single RAN solution that enables one base station to run 5G, 4G, 3G, and 2G technologies simultaneously, helping Orange Jordan achieve more efficient site solutions across their network. Orange Jordan will also utilize Nokia's NetAct network management system to enable a consolidated network view for improved network monitoring and management. Nokia will also provide digital design, deployment as well as technical support services.

07:27 EDT Xortx Therapeutics announces completion of Type D meeting with U.S. FDA - XORTX Therapeutics announces the completion of a positive and constructive Type D meeting with the U.S. Food and Drug Administration, FDA, which resulted in the identification of additional clinical endpoints potentially available for accelerated approval and further understanding of the FDA expectations for the accelerated approval of XORLO for the treatment of autosomal dominant polycystic kidney disease. The FDA Type D meeting was conducted to discuss with the agency the details of the accelerated approval process, a clinical trial protocol for the XRX-OXY-301 study, and proposed future clinical development program plans for XORLO, XORTX's proprietary oxypurinol formulation, for the treatment of ADPKD. The overall outcomes of the meeting included: 1/ Increased clarity regarding accelerated approval endpoints that would qualify for a new drug application, leading to marketing approval of XORLO for ADPKD. Phase 3 clinical trial parameters such as duration of treatment period required, follow up periods for subjects recruited into the trial and preferred statistical analysis methods, including the optimal information needed by the FDA in their decision-making process. With this information in hand, XORTX will now choose its primary clinical endpoint(s) and development strategy based on ongoing discussions with prospective partners for the asset. XORTX also intends to initiate and pursue a Special Protocol Assessment with the FDA for the XRX-OXY-301 program to further de-risk the development program for XORLO for the treatment of ADPKD.

07:26 EDT Tonix Pharmaceuticals announces IND clearance for TNX-1500 - Tonix Pharmaceuticals announced the U.S. Food and Drug Administration has cleared the Investigational New Drug, IND, application to support a Phase 1 clinical trial with TNX-1500. The first indication Tonix is seeking for TNX-1500 is the prevention of organ rejection in patients receiving a kidney transplant. The Company expects to initiate enrollment in the Phase 1 study in the third quarter of 2023. "This is an important milestone as we advance TNX-1500 into clinical development," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "Despite advancements in the field of solid organ transplantation, there remains a significant need for new treatments with improved activity and tolerability to prevent organ transplant rejection. Our primary focus of early development will be allotransplantation in which the donor organ comes from another human. However, in the longer term we hope to develop TNX-1500 for xenograft transplantation in which the donor organ comes from a genetically engineered pig."

07:24 EDT Novartis' Sandoz to exclusively commercialize six products in U.S. - Sandoz announced that it has signed a distribution and collaboration agreement with Adalvo for exclusive Sandoz rights to commercialize six products in the U.S. across key therapeutic areas, including antifungal/antibiotic, oncology and pulmonary. "These products, which are slated for near- to mid-term launches beginning in 2024, have a total addressable market size of approximately USD 3 bn, further advancing the Sandoz product pipeline in the key US generics market. The agreement also demonstrates the unwavering Sandoz commitment to pioneering patient access to critical medicines in areas of greatest unmet need. In addition to building out the Sandoz US offering in these key areas, the antibiotic products would also underpin the Sandoz strategy of combatting the global spread of antimicrobial resistance by driving responsible access to a broad range of appropriate treatments," the company stated.

07:22 EDT NFI Group provides update on credit agreement discussions - The Company's liquidity position, which combines cash on-hand plus available capacity under its credit facilities, without consideration given to the minimum liquidity requirement of $25 million under the Company's existing senior revolving credit facility and its revolving UK credit facility was $124 million as at the end of 2023 Q1, down $19 million from the end of 2022 Q4. The decrease in liquidity is primarily due to increased letters of credit being issued to support bus bids and customer prepayments, and increased debt drawings to support heightened inventory balances. These higher inventory balances primarily relate to the timing of completing vehicles that require certain components and from delays in delivering select North American battery-electric buses that require the installation of new drain technology within the battery energy enclosure system. Work on the drains began in the second quarter, and NFI expects that the majority of the vehicles impacted by these issues will commence delivery late in the second quarter and continue to be delivered throughout the rest of 2023. NFI worked with customers in the second half of 2022 and the first quarter of 2023 to seek commercial relief, and/or milestone payments, in response to rising input costs. As of April 2, 2023, the Company had received $88 million in prepayments and is continuing to work with other customers to help alleviate some of NFI's working capital investments while it navigates through supply chain challenges. NFI and its banking syndicate partners are focused on developing amended multi-year credit arrangements, and NFI is pursuing agreements that provide appropriate capacity and covenants matched to the Company's anticipated financial performance and recovery through 2025. The Company is targeting completion of these changes prior to June 30, 2023.

07:14 EDT Peloton reports 6.7M members at end of Q3 - Reports ending connected fitness subscriptions of 3.107M and net connected fitness subscription additions of 0.074M in Q3. Reports ending app subscriptions of 0.853M.

07:07 EDT C4 Therapeutics announces key upcoming milestones - CFT7455: Present Phase 1 dose escalation data from the Phase 1/2 clinical trial of Arm B1, evaluating CFT7455 as a monotherapy in MM, in the second half of 2023. CFT8634: Present Phase 1 dose escalation data from the Phase 1/2 clinical trial for synovial sarcoma and SMARCB1-null solid tumors in the second half of 2023. CFT1946: Present a Trial in Progress poster at the 2023 American Society of Clinical Oncology Annual Meeting on June 3, 2023 at 8:00 AM CST, titled "A Phase 1/2 Study of CFT1946, A Novel Bifunctional Degradation Activating Compound, or BiDAC Degrader, of Mutant BRAF V600 as Monotherapy and in Combination with Trametinib, in Mutant BRAF V600 Solid Tumors." CFT8919: Submit an Investigational New Drug application for CFT8919 for the treatment of NSCLC in the first half of 2023.

06:51 EDT Upwork announces $80M of annualized cost reductions, 15% reduction in workforce - Upwork said in its shareholder letter last night: "We remain unwavering in our commitment to building an efficient, profitable business. Steps we have taken to streamline our operations include a workforce reduction, a pause on our second-half brand media investment, considerable revisions to our hiring plans, and a reduction of vendor-related expenses. We reduced our workforce by 137 roles, or approximately 15% of full-time employees, and have also reduced positions of independent team members. We are also pausing our brand media investment indefinitely and reducing our brand working media spend by more than $22 million in the second half of 2023, representing a reduction of 94% versus the prior plan for the second half of 2023. In total, the measures announced today are expected to drive over $80 million of annualized net cost savings, and deliver approximately $40 million of net cost savings in 2023. Our second-quarter 2023 adjusted EBITDA guidance of $0 to $2 million, representing a 0% to 1% adjusted EBITDA margin, includes approximately $4 million of non-recurring severance-related costs. Excluding these non-recurring severance-related costs, our second-quarter 2023 adjusted EBITDA margin would have been expected to be 3% to 4%. These actions put us on a course to deliver fourth-quarter 2023 adjusted EBITDA margin of approximately 15% while remaining consistent with our ongoing commitment to drive durable growth and invest for strong returns."

06:47 EDT Arconic to be acquired by Apollo Funds for $30.00 per share in cash

06:37 EDT Targa Resources still sees 2023 adjusted EBITDA $3.5B-$3.7B - Now estimates total net growth capital expenditures for 2023 to be between $2.0B-$2.2B. Targa's estimate for 2023 net maintenance capital expenditures remains unchanged at approximately $175M.

06:14 EDT Ball Corp. says well positioned to achieve long-term targets - "Following our typical seasonal working capital build, we ended the first quarter with cash and available liquidity in excess of $1.5 billion. Leveraging our second half 2022 cost-out actions, contractual inflationary cost recovery and reduced capital expenditures, we remain well-positioned in 2023 to deliver our long-term diluted earnings per share goal and free cash flow in the range of $750 million in addition to returning value to shareholders," said Scott C. Morrison, executive vice president and chief financial officer.

06:05 EDT TD Bank, First Horizon terminate meger agreement - TD Bank (TD) and First Horizon (FHN) announced that they have entered into a mutual agreement to terminate their previously announced merger agreement, originally announced on February 28, 2022. TD informed First Horizon that TD does not have a timetable for regulatory approvals to be obtained for reasons unrelated to First Horizon. Because there is uncertainty as to when and if these regulatory approvals can be obtained, the parties mutually agreed to terminate the merger agreement. Under the terms of the termination agreement, TD will make a $200 million cash payment to First Horizon. This payment is in addition to the $25M fee reimbursement due to First Horizon pursuant to the merger agreement. The shares of First Horizon Series G Preferred Stock that TD Bank purchased will continue to reflect a conversion price of $25 per share. Neither party will pay any other fees or have any other liabilities to each other related to the merger agreement.

05:59 EDT Arthur J. Gallagher acquires AccurART, terms undisclosed - Arthur J. Gallagher announced the acquisition of Switzerland-based AccurART. Terms of the transaction were not disclosed. AccurART is a specialist fine arts insurance broker for private collections, museums, galleries and fine arts exhibitions, as well as offering services for jewelry, wine collections and musical instruments. It is headquartered in Zurich, Switzerland, and operates a subsidiary in Vaduz, Liechtenstein, which serves clients across Europe. Sandra Aebersold, Frank Hacker and their team will operate under the direction of Stephan Bachmann, head of Gallagher's insurance brokerage operations in Switzerland.

05:45 EDT Western Alliance issues financial update following sale of First Republic Bank - Western Alliance issued the following update in response to recent industry events. The company said, "Western Alliance released the following key financial metrics, which reinforce the Bank's strength, soundness, and stability: 1. Stable Deposits: The Bank has not experienced unusual deposit flows following the sale of First Republic Bank and other recent industry news. Total Deposits were $48.8 billion as of Tuesday, May 2, up from $48.2 billion as of Monday, May 1, and flat to Friday, April 28. Quarter to date, deposits are up $1.2 billion from $47.6 billion as of March 31. Due to normal seasonality within our mortgage warehouse business, mortgage warehouse deposits are lower from April 14 by approximately $700 million, which are rebuilding in a typical fashion and pace. Annual tax payments have also impacted deposit balances quarter-to-date. Therefore, we reaffirm our $2 billion quarter-over-quarter deposit growth rate guidance, as stated on our Q1 2023 earnings call. 2. Insured Deposit Strength: As of May 2, in accordance with regulatory requirements, insured deposits represent over 74% of total deposits, including reciprocal, collateralized, and accounts eligible for "pass-through" deposit insurance. Of our 20 largest deposit relationships, over 88% of these deposits are insured. Liquidity coverage of uninsured deposits from on-balance sheet liquidity and available borrowing capacity was approximately 165%. 3. Balance Sheet Repositioning Actions Remain on Track: The completion of $6 billion of full-year select asset dispositions discussed on our Q1 2023 earnings call remain on track. Of the $3 billion of assets previously identified as contracted to sell, but not closed, $2.1 billion have settled as of today, with the remainder expected to settle in the coming weeks. Asset disposition marks remain within the 2% average mark previously cited. 4. HFI Loan/Deposit Ratio Improvement: HFI Loans-to-Deposits were approximately 95% as of May 2 compared to approximately 98% as of March 31. 5. Strong Capital Base: Western Alliance's CET1 ratio was approximately 9.7% as of April 30 compared to 9.4% as of March 31. Our Tangible Common Equity-to-Tangible Assets ratio has increased to approximately 6.7% from 6.5% over the same time period. Acknowledging our capital strength, the Board declared our Q2 2023 common dividend of $0.36 per share on May 2, which is unchanged from Q1 2023."

05:40 EDT PacWest Bancorp provides update following sale of First Republic Bank - The company said, "In light of recent reporting regarding strategic actions, PacWest Bancorp (Nasdaq: PACW) (the "Company") provides the following update: Our message remains consistent with what was conveyed last week with earnings. As previously announced, the Company has explored strategic asset sales, including moving the $2.7 billion Lender Finance loan portfolio to held for sale in 1Q23. This planned sale remains on track and upon completion will accelerate our CET1 capital ratio to 10%+ (from 9.21% at 1Q23). Additionally, in accordance with normal practices the Company and its Board of Directors continuously review strategic options. Recently, the Company has been approached by several potential partners and investors - discussions are ongoing. The company will continue to evaluate all options to maximize shareholder value. The bank has not experienced out-of-the-ordinary deposit flows following the sale of First Republic Bank and other news. Core customer deposits have increased since March 31, 2023, with total deposits totaling $28 billion as of May 2, 2023 with insured deposits totaling 75% vs. 71% at quarter end and 73% as of April 24, 2023. In addition, the company recently paid down $1 billion of borrowings with our excess liquidity. Our cash and available liquidity remains solid and exceeded our uninsured deposits, representing 188% as of May 2, 2023. At the beginning of the year, the Company announced a new strategic plan designed to maximize shareholder value by focusing on various elements, including strengthening our community bank focus, growing our HOA business, exiting non-core products, and improving our operational efficiency. We have been executing this strategy and have accelerated many of these goals in response to recent market volatility in the banking industry."

05:26 EDT Shell announces Q1 interim dividend of 28.75c

05:22 EDT Shell reports Q1 adjusted EPS $1.39, consensus $2.11 - Reports Q1 revenue $86.96B, consensus $73.48B. The company said, "In Q1 Shell delivered strong results and robust operational performance, against a backdrop of ongoing volatility, while continuing to provide vital supplies of secure energy. We will commence a $4 billion share buyback programme for the next three months as part of our commitment to deliver attractive shareholder returns."